Acth
: Adrenocorticotropic Hormone (ACTH) is a key regulator in the hypothalamic-pituitary-adrenal (HPA) axis, but its aberrant expression is most critical in classifying pituitary adenomas and neoplasms with ectopic hormone production. Aberrant expression or modification of Acth is often implicated in the pathology of key diseases, making it a crucial biomarker and a prime focus for translational research and drug development.
The diagnostic utility of Immunohistochemistry (IHC) for Acth is unparalleled in its specific application. IHC targeting ACTH is essential for differentiating tumor subtypes, especially in complex cases like plurihormonal PitNETs (e.g., GH/ACTH co-secretion) or ‘silent’ corticotroph adenomas, which may lack clinical signs of Cushing’s disease. Accurate analysis of expression and localization using highly specific monoclonal antibodies allows researchers and pathologists to achieve superior diagnostic resolution and drive better patient stratification.
For research demanding diagnostic-grade precision, selecting a highly validated monoclonal antibody for Acth is non-negotiable. We offer these antibodies, ensuring the specificity and consistency required for both fundamental studies and clinically-relevant research. Explore our highly validated products and their detailed data sheets here: Acth Antibody Product 6010.